Transaction Advisory and Consulting
YAFO provides professional services in asset licensing, M&A, fundraising, buy-side research, commercial assessment, and pipeline strategy for global and Asian biopharma and medtech companies.
YAFO CAPITAL
Bridging Global Innovation and Life Sciences Partnerships
Bridging Global Biopharma, Medtech, and Asia
YAFO Capital
Headquartered in Shanghai, YAFO Capital is a boutique investment and advisory platform focused on cross-border transactions and global innovation partnerships in life sciences. With a global team and partner network across China, the United States, Europe, Japan, South Korea, and Southeast Asia, YAFO Capital is dedicated to connecting Asian and global biopharma, medtech, and investment ecosystems. YAFO Capital’s business spans transaction advisory and consulting, NewCo incubation, investment fund management, and industry partnering platforms. Leveraging deep sector knowledge, extensive transaction execution experience, and a broad global partner network, YAFO supports clients throughout the full transaction lifecycle, including strategy development, asset screening, deal planning, due diligence, negotiation, execution, and closing.
Our Businesses
Transaction Advisory and Consulting
YAFO provides professional services in asset licensing, M&A, fundraising, buy-side research, commercial assessment, and pipeline strategy for global and Asian biopharma and medtech companies.
YAFO Fund
YAFO invests in innovative life sciences companies and high-potential assets along with strategic industry partners.
NewCo Incubation and Innovation Collaboration
Through co-development, investment, and clinical execution support, YAFO helps global innovative assets accelerate their clinical process and maximize value through licensing, M&A, or capital partnerships
ACCESS ASIA Partnering Platform
Through virtual roadshows, in-person forums, and global industry events, ACCESS ASIA connects Asian and global pharmaceutical companies, biotech companies, investors, and strategic partners to facilitate cross-border business development and transactions.
Global Network
YAFO Capital has established a global business network across China, the United States, Europe, Japan, South Korea, and Southeast Asia. Our team and partners are active in major life sciences innovation hubs, enabling clients to efficiently access key decision-makers, strategic partners, investors, and potential transaction counterparties.
Our Team Members
Sean Jiang, CFA
Founder & CEO
20 years of Wall Street experience, banking & investment of technologies
Fan Zheng
Managing Partner, Execution
Extensive involvement and expertise in 30+ global life science licensing & cross border financial transactions
Victor Ye
Managing Partner, China Division
25+ years’ experience in Pharmaceutical industry, including the supply Chain as well as commercial and Business development
William Yao
Managing Partner, MedTech
30 years+ healthcare experience, including 7+ years in AstraZeneca China
Grace Hu, PhD, MBA
Partner, US
20+ years of experience in the healthcare industry covering drug development, sales force effectiveness, finance, strategic planning and BD
News
YAFO Capital and Princeton Global Biopharma Advisors Announce Strategic Alliance to Advance Cross-Border Biopharma Business Development
SHANGHAI, China — September 14, 2026 — YAFO Capital and Princeton Global Biopharma Advisors, LLC (“PGBA”) today announced a new strategic alliance to advance cross-border business development initiatives connecting global biopharma companies with partners in China and Asia.
View more →
YAFO Capital Shares Insights on China BD Trends and Deal Structures at CPHI Korea 2026
Seoul, South Korea — August 27, 2026 — YAFO Capital participated in CPHI Korea 2026, held from August 25–27, 2026, where its Managing Partner, Fan Zheng, was invited by CPHI Korea and the Korea Institute of Toxicology to deliver a seminar for Korean pharmaceutical and biotechnology companies. The session focused on China’s evolving innovative drug business development (BD) landscape, including China BD trends, transaction and deal structures, and key considerations for Korean companies exploring China and global partnering opportunities.
View more →